Novelix Pharmaceuticals Limited successfully conducted its Extra Ordinary General Meeting on January 9, 2026, addressing critical corporate governance matters through virtual participation. The meeting, held via video conferencing, demonstrated the company's commitment to maintaining transparent shareholder engagement while adhering to regulatory requirements.

Meeting Structure and Participation

The Extra Ordinary General Meeting commenced at 3:30 PM and concluded at 3:56 PM on January 9, 2026. A total of 64 members attended the meeting through Video Conferencing and Other Audio-Visual Means (OAVM), ensuring adequate representation for the proceedings.

Board and Leadership Attendance

The meeting witnessed comprehensive participation from the company's leadership team. Key attendees included Mr. Gattu Gnana Prakash as Director and Chairman, Mr. Venkateshwarlu Pulluru as Whole-time Director, and several other board members including Independent Director Mr. Janardhan Das Kabra and Director Mr. Jivamohan Divakar Valluri.

Additional participants comprised Ms. Sridevi Belide as Additional Director, Ms. Mayuri Baidya as Director, Ms. Nishita Kalantri as Company Secretary & Compliance Officer, and Ms. Bhoomika Choudhary as Chief Financial Officer. Mr. Bharat Khaniwal served as the appointed Scrutinizer for the voting process.

Key Agenda Items and Resolutions

The meeting focused on two primary business items, both requiring shareholder approval through electronic voting mechanisms. The agenda addressed strategic corporate decisions essential for the company's operational and governance framework.

E-Voting Process and Compliance

Novelix Pharmaceuticals implemented a comprehensive e-voting system to facilitate shareholder participation. The remote e-voting period extended from 9:00 AM on January 6, 2026, to 5:00 PM on January 8, 2026, providing members with adequate time to cast their votes.

The company engaged CDSL to provide the remote e-voting facility, ensuring technical reliability and security. Members who had not participated in remote e-voting were provided with an additional 15-minute e-voting window during the meeting itself. The combined results of both remote e-voting and meeting e-voting will be announced within 48 hours of the meeting's conclusion, with notifications sent to the stock exchange and publication on the company's website at www.novelixpharma.com .

Regulatory Compliance and Documentation

The meeting was conducted in full compliance with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013. The company maintained proper documentation and notification procedures, ensuring all stakeholders received appropriate information regarding the meeting outcomes and voting results.